AgomAb Therapeutics NV (NASDAQ:AGMB – Get Free Report) Director David Epstein bought 14,980 shares of AgomAb Therapeutics stock in a transaction on Friday, November 13th. The stock was purchased at an average price of $5.92 per share, with a total value of $88,681.60. Following the completion of the acquisition, the director directly owned 54,980 shares of the company’s stock, valued at $325,481.60. This represents a 37.45% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
AgomAb Therapeutics Stock Performance
NASDAQ:AGMB opened at $6.36 on Monday. AgomAb Therapeutics NV has a fifty-two week low of $5.73 and a fifty-two week high of $17.82. The company’s 50-day simple moving average is $9.57 and its 200-day simple moving average is $11.73.
Analyst Upgrades and Downgrades
AGMB has been the topic of a number of recent analyst reports. Piper Sandler assumed coverage on AgomAb Therapeutics in a research report on Tuesday, August 25th. They set an “overweight” rating and a $60.00 price target on the stock. Wall Street Zen downgraded AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, September 27th. HC Wainwright restated a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday, October 21st. Cantor Fitzgerald started coverage on shares of AgomAb Therapeutics in a research report on Wednesday, August 19th. They issued an “overweight” rating for the company. Finally, Johnson Rice reiterated a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday, October 21st. Eight analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.50.
About AgomAb Therapeutics
Agomab Therapeutics is a clinical-stage biopharmaceutical company developing medicines for fibrotic and inflammatory diseases. Its research focuses on growth-factor pathways involved in tissue repair and fibrosis. The company’s pipeline includes AGMB-129, an oral, gut-restricted inhibitor of the TGF-β receptor ALK5 being developed for fibrostenotic Crohn’s disease, and AGMB-447, an inhaled therapy targeting integrins for fibrotic lung disease. Agomab is also developing antibody-based approaches to fibrosis.
Read More
- Five stocks we like better than AgomAb Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for AgomAb Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgomAb Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
